Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma

Press/Media

Period	13 Feb 2023

Media coverage

Title	Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma
Media name/outlet	MENAFN -Press Releases (English)
Country/Territory	Jordan
Date	13/02/23
URL	ct.moreover.com/?a=50308927863&p=1gw&v=1&x=wgkdhHqx650i-HLIoBN4Lw
Persons	Mauricio Burotto